pepito (pandorum - symetry) is a fraud

Insiders buying = Indirect Ownership - Acquisition carried out privately

500 000 000 o/s soon

Another 540 000 has been added last week

Day traders and speculators will leave the board and the stock soon, can you see it?

I can show you a dozen of reports where these guys are wrong

New readers and potential investors have to know that Paradigm is always wrong.

Wrong in 2002
Wrong in 2005
Wrong in 2006
Wrong in 2007
Wrong in 2008

I have news for you my friend, in 2002, Paradigm gave Prometic a $9 target price, which was also clearly explained...
-balin
.
SUBJECT: Paradigm price target is 1.25$! Posted By: MBAtrader
Post Time: 3/10/2006 05:04
.
http://www.newratings.com/analyst_news/article_1157127.html

ProMetic Life target price reduced
Friday, December 09, 2005 10:08:28 AM ET
Paradigm

NEW YORK, December 09 (newratings.com) - Analysts at Paradigm have reduced their target price for ProMetic Life (ticker: PLI.SV.T) to C$1.25

This message (Post #11630329)
--------------------------------------------------------------------------
Claude Camiré 1 February 14, 2007
Senior HealthCare Analyst (416) 360-1322
Prometic Life Sciences Inc.

(PLI-T
.51)
Ready For The "1402 Boost"

We are raising our target price from
.80 to $2.00 for PLI ahead of the first set of clinical trial results (Phase Ib/IIa) expected in H2/FY07 and the increased likelihood of partnership for PBI-1402. We maintain our Buy rating.

Stock Rating:
Buy
12-month target ??$ 2.00
-----------------------------------------------------------------------------
Claude Camiré 1 October 17, 2007

(PLI-T
.37)
.
• Maintaining our Buy recommendation and increasing our
target price from $2.00 to $3.00.
------------------------------------------------------------------
Paradigm Capital Inc, IDA/TSX member 1 December 12, 2007
.
ProMetic Life Sciences Inc.

(PLI-T
.52)

Recommendation:

Buy

12-month target $3.00
--------------------------------------------------------------------------
Paradigm Capital Inc, IDA/TSX member 1 February 26, 2008

Claude Camiré, Senior HealthCare Analyst (416) 360 – 1322

(PLI-T
.48)

Recommendation:

Buy

12-month target $3.00
-------------------------------------------------------------------------------------------
Paradigm Capital Inc, IIROC/TSX member 1

Claude Camiré, Analyst 416.360.1322

August 6, 2008

Stock Rating:

12- target (C$) $3.00
------------------------------------------------------------------------------
Paradigm Capital Inc, IIROC/TSX member 1

Claude Camiré, Analyst 416.360.1322

August 15, 2008

- Buy rating maintained but target price reduced from $3.00 to

$2.00 due to delays in revenue ramp-up.